ECSP088867A - Derivados de pirimidina como inhibidores de fi3q - Google Patents
Derivados de pirimidina como inhibidores de fi3qInfo
- Publication number
- ECSP088867A ECSP088867A EC2008008867A ECSP088867A ECSP088867A EC SP088867 A ECSP088867 A EC SP088867A EC 2008008867 A EC2008008867 A EC 2008008867A EC SP088867 A ECSP088867 A EC SP088867A EC SP088867 A ECSP088867 A EC SP088867A
- Authority
- EC
- Ecuador
- Prior art keywords
- group
- substituted
- alkyl
- alq
- unsubstituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
Abstract
Tienopirimidinas de formula (Ia) o (Ib): donde R1 es un grupo de fórmula: R2 es halo o alquilo C1-C6; R3 es un grupo indol, el cual está sustituido o no sustituido; La forma R4 y R5, junto con el átomo N al que se adjunta, un grupo seleccionado de piperazina, y piperidina y pirrolidina, cuyo grupo están sustituidos o no sustituidos por uno o más grupos seleccionados de alquilo C1-C6,-S (O) 2 R 10, S-(O) 2 - (alq)q -Het, un grupo heterociclo y -NR13R14; o uno de R4 y R5 es alquilo C1-C6, y el otro es un grupo piperazina, piperidina o pirrolidina, que es un grupo sustituído o no sustituido; R10 es H o alquilo C 1-C6 que no está sustituído; R 11 y R 12 se seleccionaron de forma independiente cada uno de H y alquilo C1-C6 que no está sustituído, o R11 y R12 juntos forman, con el átomo N al cual están adjuntos, un grupo heterocíclico saturado de 5- o 6 miembros; R13 y R14 se seleccionaron cada uno de forma independiente de alquilo C1-C6, -S (O)2 R10, alq-OR10, - (alq)q-F y -(alq)q-Het; F es fenilo; q es 0 o 1; Het es un grupo tiazol, imidazol, pirrol, piridina o pirimidina, el cual está sustituido o no sustituido; y Alq es alquileno C1-C6;o una sal farmacéuticamente aceptable del mismo que tiene actividad como inhibidores de FI3Q y puede ser usada para tratar enfermedades y desórdenes derivados del crecimiento, función o comportamiento celular anormal asociada con FI3 quinasa, en particular el subtipo delta p110 , tales como inmuno desórdenes, enfermedades cardiovasculares, infección viral, inflamación, desórdenes del metabolismo/endocrinología o desórdenes neurológicos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0608264A GB0608264D0 (en) | 2006-04-26 | 2006-04-26 | Pharmaceutical compounds |
GB0608397A GB0608397D0 (en) | 2006-04-27 | 2006-04-27 | Pharmaceutical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP088867A true ECSP088867A (es) | 2008-12-30 |
Family
ID=38110021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2008008867A ECSP088867A (es) | 2006-04-26 | 2008-11-05 | Derivados de pirimidina como inhibidores de fi3q |
Country Status (15)
Country | Link |
---|---|
US (2) | US8252792B2 (es) |
EP (1) | EP2032582A1 (es) |
JP (1) | JP5302186B2 (es) |
KR (1) | KR20090021155A (es) |
AU (1) | AU2007242594A1 (es) |
BR (1) | BRPI0710866A2 (es) |
CA (1) | CA2650196A1 (es) |
CR (1) | CR10369A (es) |
EC (1) | ECSP088867A (es) |
IL (1) | IL194755A0 (es) |
MA (1) | MA30360B1 (es) |
MX (1) | MX2008013582A (es) |
NO (1) | NO20084832L (es) |
RU (1) | RU2008141356A (es) |
WO (1) | WO2007122410A1 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007243457B2 (en) | 2006-04-26 | 2012-02-23 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
BRPI0717907A2 (pt) | 2006-12-07 | 2013-11-05 | Genentech Inc | "composto, composição farmacêutica, métodos para tratar um câncer, para inbir ou modular a atividade da lipídeo quinase, processo para a produçãoo de uma composição farmacêutica, uso de um composto e kit" |
JP5284977B2 (ja) | 2006-12-07 | 2013-09-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ホスホイノシチド3−キナーゼ阻害剤化合物及び使用方法 |
CN101679456B (zh) * | 2007-06-12 | 2012-09-05 | 霍夫曼-拉罗奇有限公司 | 噻唑并嘧啶类和它们作为磷脂酰肌醇3-激酶的抑制剂的应用 |
BRPI0816769A2 (pt) | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso |
CN101932587A (zh) | 2007-09-24 | 2010-12-29 | 吉宁特有限公司 | 噻唑并嘧啶pi3k抑制剂化合物及使用方法 |
WO2009055730A1 (en) * | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
GB0721095D0 (en) * | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
RU2473549C2 (ru) | 2008-07-31 | 2013-01-27 | Дженентек, Инк. | Пиримидиновые соединения, композиции и способы применения |
US8778927B2 (en) | 2008-10-01 | 2014-07-15 | Novartis Ag | Smoothened antagonism for the treatment of hedgehog pathway-related disorders |
TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
DK2385832T3 (en) | 2009-01-08 | 2015-09-21 | Curis Inc | Phosphoinositid-3-kinase-inhibitorer med en zink-bindingsdel |
CA2761445A1 (en) | 2009-05-27 | 2010-12-02 | Genentech, Inc. | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
EP2451811A1 (en) | 2009-05-27 | 2012-05-16 | F. Hoffmann-La Roche AG | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
JP5721706B2 (ja) * | 2009-06-17 | 2015-05-20 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | インフルエンザウイルス複製の阻害剤 |
AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
MX2012002059A (es) | 2009-08-20 | 2012-04-19 | Karus Therapeutics Ltd | Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa. |
BR112012011188A2 (pt) | 2009-11-12 | 2021-06-29 | F.Hoffmann - La Roche Ag | ''composto,composição farmacêutica e uso de um composto" |
CN102712642B (zh) | 2009-11-12 | 2015-08-12 | 霍夫曼-拉罗奇有限公司 | N-7取代的嘌呤和吡唑并嘧啶化合物、组合物和使用方法 |
BR112013014914B8 (pt) | 2010-12-16 | 2020-08-04 | Hoffmann La Roche | composto, composição farmacêutica e uso de um composto |
UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
KR101761464B1 (ko) | 2012-05-23 | 2017-07-25 | 에프. 호프만-라 로슈 아게 | 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법 |
US20150258127A1 (en) | 2012-10-31 | 2015-09-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
US9676765B2 (en) | 2012-11-07 | 2017-06-13 | Karus Therapeutics Limited | Histone deacetylase inhibitors and their use in therapy |
WO2014181137A1 (en) | 2013-05-10 | 2014-11-13 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors |
US9296727B2 (en) | 2013-10-07 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines |
CN105849100B (zh) | 2013-11-13 | 2019-07-16 | 沃泰克斯药物股份有限公司 | 流感病毒复制抑制剂 |
SI3421468T1 (sl) | 2013-11-13 | 2021-03-31 | Vertex Pharmaceuticals Incorporated | Postopki za pripravo inhibitorjev replikacije virusov influence |
GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
DK3230289T3 (da) | 2014-12-11 | 2019-10-28 | Natco Pharma Ltd | 7-(Morpholinyl)-2-(N-piperazinyl)-methylthieno-2, 3-c]pyridinderivativer som anticancer-lægemidler |
WO2016147543A1 (en) | 2015-03-13 | 2016-09-22 | Ricoh Company, Ltd. | Electrochromic compound, electrochromic composition, electrochromic element, and electrochromic dimming element |
EP3294717B1 (en) | 2015-05-13 | 2020-07-29 | Vertex Pharmaceuticals Inc. | Methods of preparing inhibitors of influenza viruses replication |
JP6857617B2 (ja) | 2015-05-13 | 2021-04-14 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | インフルエンザウイルスの複製の阻害剤 |
GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
US10562849B2 (en) * | 2016-05-16 | 2020-02-18 | The Board Of Regents Of The University Of Texas System | Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids |
IL307871A (en) * | 2021-04-21 | 2023-12-01 | Natco Pharma Ltd | PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69943144D1 (de) | 1998-03-31 | 2011-03-03 | Kyowa Hakko Kirin Co Ltd | Stickstoffenthaltende heterocyclische verbindungen |
US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
EP1277738B1 (en) * | 2000-04-27 | 2011-03-30 | Astellas Pharma Inc. | Condensed heteroaryl derivatives |
WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
GB0423653D0 (en) * | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
AU2007243457B2 (en) | 2006-04-26 | 2012-02-23 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
-
2007
- 2007-04-25 KR KR1020087028890A patent/KR20090021155A/ko not_active Application Discontinuation
- 2007-04-25 EP EP07732542A patent/EP2032582A1/en not_active Withdrawn
- 2007-04-25 WO PCT/GB2007/001504 patent/WO2007122410A1/en active Application Filing
- 2007-04-25 RU RU2008141356/04A patent/RU2008141356A/ru not_active Application Discontinuation
- 2007-04-25 BR BRPI0710866-4A patent/BRPI0710866A2/pt not_active Application Discontinuation
- 2007-04-25 JP JP2009507152A patent/JP5302186B2/ja not_active Expired - Fee Related
- 2007-04-25 US US12/298,507 patent/US8252792B2/en not_active Expired - Fee Related
- 2007-04-25 CA CA002650196A patent/CA2650196A1/en not_active Abandoned
- 2007-04-25 MX MX2008013582A patent/MX2008013582A/es not_active Application Discontinuation
- 2007-04-25 AU AU2007242594A patent/AU2007242594A1/en not_active Abandoned
-
2008
- 2008-10-15 CR CR10369A patent/CR10369A/es not_active Application Discontinuation
- 2008-10-22 IL IL194755A patent/IL194755A0/en unknown
- 2008-10-27 MA MA31338A patent/MA30360B1/fr unknown
- 2008-11-05 EC EC2008008867A patent/ECSP088867A/es unknown
- 2008-11-18 NO NO20084832A patent/NO20084832L/no not_active Application Discontinuation
-
2012
- 2012-07-19 US US13/553,650 patent/US8697693B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
IL194755A0 (en) | 2009-08-03 |
MX2008013582A (es) | 2009-01-19 |
KR20090021155A (ko) | 2009-02-27 |
CR10369A (es) | 2009-01-09 |
JP5302186B2 (ja) | 2013-10-02 |
US8697693B2 (en) | 2014-04-15 |
MA30360B1 (fr) | 2009-04-01 |
RU2008141356A (ru) | 2010-06-10 |
BRPI0710866A2 (pt) | 2012-08-14 |
WO2007122410A1 (en) | 2007-11-01 |
CA2650196A1 (en) | 2007-11-01 |
US8252792B2 (en) | 2012-08-28 |
AU2007242594A1 (en) | 2007-11-01 |
EP2032582A1 (en) | 2009-03-11 |
US20120283257A1 (en) | 2012-11-08 |
JP2009534453A (ja) | 2009-09-24 |
NO20084832L (no) | 2008-11-18 |
US20100016306A1 (en) | 2010-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP088867A (es) | Derivados de pirimidina como inhibidores de fi3q | |
PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
AR087919A1 (es) | Heterociclos biciclicos como inhibidores de irak4 | |
AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
AR095312A1 (es) | Compuestos de biarilamida como inhibidores de cinasa | |
AR054127A1 (es) | Imidazoquinolinas como inhibidores de quinasa de lipido | |
AR062125A1 (es) | Compuestos que modulan el receptor cb2 y su utilizacion como medicamentos | |
MX2013004407A (es) | Derivado de piridina y agente medicinal. | |
DE602005016775D1 (de) | Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion | |
AR050953A1 (es) | Compuestos de sulfonamida inhibidores de los receptores de cck1/cck2 duales | |
CO6231035A2 (es) | Novedoso compuesto heteromonociclico que tiene propiedades superiores como agente farmaceutico | |
HRP20090533T1 (en) | Indolyl derivatives as liver-x-receptor modulators | |
PE20011039A1 (es) | Tiazoles e imidazopiridinas como inhibidores de la produccion de tnf | |
AR057023A1 (es) | Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa | |
PE20141059A1 (es) | Indazoles | |
CO6260074A2 (es) | Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa | |
CO6341631A2 (es) | Derivados de 1,2,4 - oxadiazol y su uso terapéutico | |
CO6251248A2 (es) | Compuestos de tiazolopiridina como moduladores de sirtuina | |
AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
AR055144A1 (es) | Inhibidor de secrecion acida | |
AR070460A1 (es) | Compuestos inhibidores de erk y composiciones farmaceuticas que los contienen | |
PE20161476A1 (es) | Derivados de indolin-2-ona o pirrolo-piridin-2-ona | |
AR079496A1 (es) | Derivados de aril triazol heteroaromaticos como inhibidores de enzima pde10a | |
PE20120655A1 (es) | Derivados de triazolopiridina como inhibidores de proteinas cinasas activadas por mitogeno p38 (map) | |
NZ599342A (en) | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors |